TENX · Insider Trading
Tenax Therapeutics, Inc.
Every open-market purchase and sale reported by TENX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +922,849 | +$1.46M |
| 2026-09-17 | Declan Doogan | Director | Buy | +53,000 | +$101.76K |
| 2026-09-15 | Thomas R Staab II | Chief Financial Officer | Buy | +5,675 | +$10.98K |
| 2026-09-15 | Christopher Thomas Giordano | CEO | Buy | +10,850 | +$20.09K |
| 2026-09-08 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | +900,000 | +$1.60M |
| 2026-09-02 | Daniel Schneeberger | 10%+ Owner | Buy | +770,333 | +$1.38M |
| 2026-08-24 | Daniel Schneeberger | 10%+ Owner | Buy | +1,025,867 | +$1.81M |
| 2026-07-14 | Christopher Thomas Giordano | CEO | M | +8,719 | +$51.27K |
| 2026-05-13 | Thomas R Staab II | Chief Financial Officer | A | +10,000 | — |
| 2026-02-03 | Thomas McGauley | Interim CFO | M | — | — |
| 2026-01-13 | June Sherie Almenoff | Director | A | — | — |
| 2026-01-13 | Gerald T Proehl | Director | A | — | — |
| 2026-01-13 | Declan Doogan | Director | A | — | — |
| 2026-01-13 | Michael H. Davidson | Director | A | — | — |
| 2026-01-13 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2026-01-13 | Robyn Hunter | Director | A | +30,000 deriv. | — |
| 2026-01-13 | Christopher Thomas Giordano | CEO | A | — | — |
| 2025-12-10 | Stuart Rich | Chief Medical Officer | Buy | +5,000 | +$50.79K |
| 2025-12-05 | Stuart Rich | Chief Medical Officer | Buy | +5,000 | +$45.62K |
| 2025-11-20 | June Sherie Almenoff | Director | Buy | +1,993 | +$14.94K |
| 2025-11-20 | Christopher Thomas Giordano | CEO | Buy | +2,605 | +$20.00K |
| 2025-11-19 | Thomas McGauley | Interim CFO | Buy | +8,000 | +$58.16K |
| 2025-11-19 | June Sherie Almenoff | Director | Buy | +1,993 | +$14.94K |
| 2025-07-03 | June Sherie Almenoff | Director | A | +80,000 deriv. | — |
| 2025-07-03 | Michael H. Davidson | Director | A | — | — |
| 2025-07-03 | Robyn Hunter | Director | A | +80,000 deriv. | — |
| 2025-07-03 | Gerald T Proehl | Director | A | — | — |
| 2025-07-03 | Declan Doogan | Director | A | — | — |
| 2025-05-20 | Christopher Thomas Giordano | CEO | A | +1,400,000 deriv. | — |
| 2025-05-20 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2024-12-12 | June Sherie Almenoff | Director | A | +100,000 deriv. | — |
| 2024-12-12 | Declan Doogan | Director | A | — | — |
| 2024-12-12 | Christopher Thomas Giordano | CEO | A | +1,250,000 deriv. | — |
| 2024-12-12 | Robyn Hunter | Director | A | +100,000 deriv. | — |
| 2024-12-12 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2024-12-12 | Michael H. Davidson | Director | A | — | — |
| 2024-12-12 | Gerald T Proehl | Director | A | — | — |
| 2024-05-21 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2024-05-21 | Christopher Thomas Giordano | CEO | A | +437 deriv. | — |
| 2022-09-23 | Stuart Rich | Chief Medical Officer | G | — | — |
| 2022-08-12 | Declan Doogan | Director | G | — | — |
| 2022-06-10 | Christopher Thomas Giordano | CEO | A | +200,000 deriv. | — |
| 2022-06-10 | Robyn Hunter | Director | A | +6,250 deriv. | — |
| 2022-06-10 | June Sherie Almenoff | Director | A | +5,000 deriv. | — |
| 2022-06-10 | Gerald T Proehl | Director | A | — | — |
| 2022-06-10 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2022-06-10 | Declan Doogan | Director | A | — | — |
| 2022-06-10 | Michael H. Davidson | Director | A | — | — |
| 2022-05-19 | Steven Boyd | Director | MIXED | +21,192,054 deriv. | — |
| 2021-12-06 | Stuart Rich | Chief Medical Officer | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| ADAR1 Capital Management, LLC | 10%+ Owner | 7,115,021 | — |
| Daniel Schneeberger | 10%+ Owner | 5,257,389 | $9.36M |
| Declan Doogan | Director | 55,274 | $98.39K |
| Christopher Thomas Giordano | CEO | 17,324 | $30.84K |
| Thomas R Staab II | Chief Financial Officer | 15,675 | $27.90K |
| Thomas McGauley | Interim CFO | 7,000 | $12.46K |
| Stuart Rich | Chief Medical Officer | 6,460 | $11.50K |
| June Sherie Almenoff | Director | 3,986 | $7.10K |
| Michael H. Davidson | Director | 2,881 | $5.13K |
| Gerald T Proehl | Director | 1,667 | $2.97K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TENX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.